Genentech, Roche vets aim new company’s $86.25 million IPO at cancer

/Genentech, Roche vets aim new company’s $86.25 million IPO at cancer

Genentech, Roche vets aim new company’s $86.25 million IPO at cancer

A South San Francisco startup led by veterans of biotech stalwart Genentech Inc. and its parent company Roche wants to raise $86.25 million in an initial public offering. RAPT Therapeutics Inc. — known until May as FLX Bio Inc. — expects to use the IPO booty to fund development of cancer-fighting FLX-475 through results of an ongoing Phase I/II clinical trial, fund an early-stage safety trial of RPT-193 in the itchy skin condition known as atopic dermatitis and develop other drug candidates,…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2019-07-05T21:51:40+00:00 July 5th, 2019|Uncategorized|

About the Author: